Depletion of Phosphatidylinositol 4,5-Bisphosphate by Activation of Phospholipase C-coupled Receptors Causes Slow Inhibition but Not Desensitization of G Protein-gated Inward Rectifier K+ Current in Atrial Myocytes*

Thomas Meyer, Marie-Cécile Wellner-Kienitz, Anke Biewald, Kirsten Bender, Andreas Eickel, and Lutz PottDagger

From the Institut für Physiologie, Ruhr-Universität Bochum, D44780 Bochum, Germany

Received for publication, October 9, 2000, and in revised form, November 14, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

G protein-gated inwardly rectifier K+ current in atrial myocytes (IK(ACh)) upon stimulation with acetylcholine (ACh) shows a fast desensitizing component (t1/2 ~ 5 s). After washout of ACh, IK(ACh) recovers from fast desensitization within < 30 s. A recent hypothesis suggests that fast desensitization is caused by depletion of phosphatidylinositol 4,5-bisphosphate (PtIns(4,5)P2), resulting from costimulation of phospholipase C (PLC)-coupled M3 receptors (M3AChR). The effects of stimulating two established PLC-coupled receptors, alpha -adrenergic and endothelin (ETA), on IK(ACh) were studied in rat atrial myocytes. Stimulation of these receptors caused activation of IK(ACh) and inhibition of the M2AChR-activated current. In myocytes loaded with GTPgamma S (guanosine 5'-3-O-(thio)triphosphate), causing stable activation of IK(ACh), inhibition via alpha -agonists and ET-1 was studied in isolation. Stimulation of either type of receptor under this condition, via Gq/11, caused a slow inhibition (t1/2~50 s) by about 70%. No comparable effect on GTPgamma S-activated IK(ACh) was induced by ACh, suggesting that PLC-coupled M3AChRs are not functionally expressed in rat myocytes, which was supported by the finding that M3AChR transcripts were not detected by reverse transcriptase-polymerase chain reaction in identified atrial myocytes. Supplementing the pipette solution with PtIns(4,5)P2 significantly reduced inhibition of IK(ACh) but had no effect on fast desensitization. From these data it is concluded that stimulation of PLC-coupled receptors causes slow inhibition of IK(ACh) by depletion of PtIns(4,5)P2, whereas fast desensitization of IK(ACh) is not related to PtIns(4,5)P2 depletion. As muscarinic stimulation by ACh does not exert inhibition of IK(ACh) comparable to stimulation of alpha 1- and ETA receptors, expression of functional PLC-coupled muscarinic receptors in rat atrial myocytes is unlikely.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In the heart, predominantly in supraventricular tissue, in various neurons and endocrine cells, stimulation of receptors coupled to pertussis toxin-sensitive G proteins (Gi/o) activates G protein-gated inward rectifying K+ (GIRK)1 channels, resulting in reduction of excitability (1-3). Upon exposure of a myocyte to an appropriate receptor agonist, the current is activated within less than 1 s. Activation is followed by desensitization, i.e. a decay of current, made up of several components with different kinetics of onset and recovery (4). Slow components seem to represent receptor desensitization, presumably mediated by phosphorylation via receptor kinase(s) and subsequent events such as receptor internalization and down-regulation (5, 6), but a fast component, developing with a time constant in the range of seconds, is localized downstream of the activating receptor. Several mechanisms have been proposed for fast desensitization. Shui et al. (7) suggested channel dephosphorylation as the underlying mechanism, whereas Hong et al. (8) reported the contribution of a nonidentified cytosolic protein. The major properties of fast desensitization, such as the rate of current decay, its membrane-delimited nature, and its dependence on receptor density, can be accounted for by a model relating fast desensitization, analogous to activation, to the nucleotide exchange and hydrolysis cycle of the G protein (9). More recently, an attractive novel mechanism has been proposed (10). These authors suggested that activation and fast desensitization of atrial IK(ACh) result from costimulation of two muscarinic receptors: the M2 subtype (M2AChR) which causes activation via Gi/o, whereas stimulation of the M3 subtype (M3AChR) via activation of Gq/11 stimulates phospholipase C (PLC) and subsequent depletion of phosphatidylinositol bisphosphate (PtIns(4,5)P2) in the inner leaflet of the membrane. Such a mechanism would be in line with the finding that PtIns(4,5)P2 is an important cofactor for activation of GIRK channels (11-13) and other members of the Kir channel family (14-16) and supports the notion that PtIns(4,5)P2 meets the criteria of a receptor-controlled second messenger (17). However, this hypothesis is inconsistent with one major property of acute desensitization, namely its heterologous nature. In atrial cells IK(ACh) can be activated not only by M2AChR but also, e.g. by A1 adenosine receptors (18, 19) and a sphingolipid receptor of the EDG family (20, 21). These studies have shown that ACh rapidly desensitizes the response to Ado and vice versa; correspondingly, sphingosine 1-phosphate, presumably via a receptor of the EDG family (22), desensitizes the response to ACh and vice versa. In rat atrial myocytes overexpression of A1-receptors, a classic Gi/o-coupled species, not only increased density of Ado-induced IK(ACh) but also substantially enhanced fast desensitization of current activated via stimulation of this receptor (19).

In the present study we investigated the effect of stimulating two different intrinsic Gq/11-coupled receptors on IK(ACh) in atrial myocytes. The results support the notion that stimulation of the PLC pathway via depletion of PtIns(4,5)P2 causes inhibition of IK(ACh). However, this inhibition is slower than fast desensitization by a factor of 10. Moreover there is no evidence of significant expression of functional expression of a Gq/11-coupled muscarinic receptor, such as M3AchR, in rat atrial myocytes.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Isolation and Culture of Atrial Myocytes-- Experiments were performed with local ethics committee approval. Wistar Kyoto rats of either sex (around 200 g) were anesthetized by intravenous injection of urethane (1 g/kg). The chest was opened, and the heart was removed and mounted on the cannula of a sterile Langendorff apparatus for coronary perfusion at constant flow. The method of enzymatic isolation of atrial myocytes has been described elsewhere (see Ref. 4). The culture medium was fetal calf serum-free bicarbonate-buffered M199 (Life Technologies, Inc.) containing 25 µg/ml gentamycin (Sigma) and 25 µg/ml kanamycin (Sigma). Cells were plated at a low density (several thousand cells/dish) on 36-mm culture dishes. Medium was changed 24 h after plating and then every 2nd day. Myocytes were used experimentally from day 0 until day 4 after isolation. No effects of time in culture were found for the key experiments.

Solutions and Chemicals-- For the patch clamp measurements an extracellular solution of the following composition was used (in mM): 120 NaCl, 20 KCl, 2.0 CaCl2, 1.0 MgCl2, 10.0 Hepes/NaOH, pH 7.4. The solution for filling the patch clamp pipettes for whole cell voltage clamp experiments contained (in mM) 110 potassium aspartate, 20 KCl, 10 NaCl, 1.0 MgCl2, 2.0 MgATP, 2.0 EGTA, 0.01 GTP or 0.5 GTPgamma S, 10.0 Hepes/KOH, pH 7.4. Standard chemicals for electrophysiological experiments were from Merck (Darmstadt, Germany). EGTA, Hepes, MgATP, adenosine, GTP, acetylcholine chloride, phenylephrine, methoxamine, and endotheline-1 were from Sigma; PtIns(4,5)P2, Pasteurella multocida toxin and U23187 were from Calbiochem. 4-Diphenylacetoxy-N-methypiperidine (4-DAMP) was from Tocris. Drugs were prepared as concentrated stock solutions either in distilled water or dimethyl sulfoxide. PtIns(4,5)P2 was dissolved in pipette solution at a nominal concentration of 500 µM. The solution was sonicated intermittently on ice for 30 min. Sonification was repeated each time before filling a new pipette. PtIns(4,5)P2 solutions were used for 1 day only.

Current Measurement-- Membrane currents were measured using whole cell patch clamp. Pipettes were fabricated from borosilicate glass and were filled with the solution listed above (DC resistance 4-6 megohms). Currents were measured by means of a patch clamp amplifier (LM/EPC 7, Darmstadt, Germany). Signals were analog filtered (corner frequency of 1-3 kHz), digitally sampled at 5 kHz, and stored on a computer, equipped with a hardware/software package (ISO2 by MFK, Frankfurt/Main, Germany) for voltage control and data acquisition. Experiments were performed at ambient temperature (22-24 °C). Cells were voltage clamped at -90 mV, i.e. negative to EK (-50 mV), resulting in inward K+ currents. Current-voltage relations were determined by means of voltage ramps from -120 mV to +60 mV. Rapid superfusion of the cells for application and withdrawal of different solutions was performed by means of a custom made solenoid-operated flow system that permitted switching between up to six different solutions (t1/2 <=  100 ms). Performance of this system was dependent on the positioning of the outlet tube in relation to the cell studied. This was routinely optimized by measuring the time course of the blocking action of Ba2+ on IK(ACh). As shown previously, activation kinetics of IK(ACh) was not limited by the rate of agonist application (19).

RT-PCR-- RNA from cell samples was isolated using Trizol reagent (Life Technologies, Inc.). RNA in 20 µl of RNase-free H2O (Qiagen, Hilden, Germany) was treated with 7.5 units of DNase I (Amersham Pharmacia Biotech) for 15 min at 37 °C. DNase was inactivated by adding 2.5 µl of 25 mM EDTA and heating at 65 °C for 10 min.

The culture medium was replaced by rinsing the cells for 30 min with a solution containing (in mM): 120 NaCl, 20 KCl, 2 CaCl2, 1 MgCl2, 10 Hepes/NaOH, pH 7.4. 0.1% diethyl pyrocarbonate was added. The solution was autoclaved before use. 10 myocytes were aspirated into glass capillaries with a ~30-µm tip diameter using a water hydraulic micromanipulator attached to an inverted microscope. Alternatively, the cells were scratched from the dish, and a corresponding volume of the cell suspension was aspirated, which should contain also nonmyocyte cells. Capillaries were rinsed with hexamethyldisilazane (Sigma) and baked for 7 h at 240 °C before use. The content of the capillary (<0.5 µl) was expelled into a tube filled with 5 µl of lysis buffer containing: 0.8% (w/v) Nonidet P-40 substitute (Fluka, Buchs, Switzerland), 100 µg/ml yeast tRNA, 10 mM dithiothreitol (both from Life Technologies, Inc.), and 8 units/µl RNAguard (Amersham Pharmacia Biotech).

In the experiments on selected myocytes 2.5 µl of RNase-free H2O (Qiagen) and 0.5 µl of oligo(dT)15 primer (500 µg/ml; Promega, Madison, WI) were added to the lysis solution and incubated at 42 °C for 10 min. 11 µl of RT mixture was added, containing 2.4 µl of RNase-free H2O, 4 µl of first strand buffer (5-fold), 2 µl of dithiothreitol (100 mM), 1 µl of SuperScript II RT (200 units/µl; all from Life Technologies, Inc.) and 1.6 µl of dNTP mixture (6.25 mM each; Epicentre Technologies, Madison, WI). The RNA was transcribed for 1 h at 42 °C. The reaction was stopped by heating to 95 °C for 10 min.

The extracted RNA from suspended atrial cultures (see above) was transcribed by adding 10 µl of first strand buffer, 0.5 µl of SuperScript II RT, 5 µl of dithiothreitol, 1.6 µl of dNTP mixture, 1.6 µl of oligo(dT)15 primer, 0.5 µl of RNAguard, and 7.2 µl of RNase-free H2O (same reagents as above). The sample was incubated at 42 °C for 1 h before heat inactivation at 95 °C for 10 min.

cDNA from the myocyte RT was amplified by dividing the content of the RT tube into two aliquots of 9.5 µl and adding 40.5 µl of PCR mixture to each tube. The PCR mixture contained 34 µl of distilled water (Life Technologies, Inc.), 0.5 µl of Taq DNA polymerase (5,000 units/ml), 5 µl of PCR buffer (10-fold; both Amersham Pharmacia Biotech), 0.5 µl of sense primer, 0.5 µl of antisense primer (both 100 pmol/µl; Life Technologies, Inc.), either for M3AChR and GAPDH or M2AChR and GAPDH.

PCR from cDNA of atrial cell suspension RT was performed by mixing 1 µl of RT product, 16 µl of distilled water, 2 µl of PCR buffer, 0.4 µl of dNTP mixture, 0.2 µl of M3 primer (sense), 0.2 µl of M3 primer (antisense), and 0.2 µl of Taq DNA polymerase (same reagents as above).

The sequences of primers were as follows: M2AChR, 5'-TGGCTTGGCTATTACCAGTC-3' (sense) and 5'- ACGATGAACTGCCAGAAGAG-3' (antisense); M3AChR, 5'-GTCGCTGTCACTTCTGGTTC-3' (sense) and 5'-CGGCAGACTCTAACTGGATG-3' (antisense); GAPDH, 5'-TCCGCCCCTTCCGCTGAT-3' (sense) and 5'-CACGGAAGGCCATGCCAGTGA-3' (antisense). The primers amplify a 340-base pair fragment of GAPDH, a 468-base pair fragment of M2AChR, and a 378-base pair fragment of M3AChR. Samples were overlaid with mineral oil and incubated in a thermal cycler (PTC-150, MJ Research, Watertown, MA), first for 5 min at 94 °C, followed by 50 cycles for 45 s at 94 °C, 1 min at 52 °C, 2 min at 72 °C, and a final extension at 72 °C at 10 min. 10 µl of RT-PCR products was subjected to electrophoresis on a 2% agarose gel, stained with ethidium bromide, and photographed under UV transillumination.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Definition of Fast Desensitization of Atrial IK(ACh)-- As shown previously, atrial IK(ACh) in the presence of an agonist shows different components of desensitization, depending on multiple factors such as agonist concentration, receptor density, speed, and duration of agonist exposure (4, 19, 23). The slower components, occurring upon agonist exposure on a time scale of minutes to hours, are supposed to reflect receptor desensitization, analogous to other receptor-G protein-effector pathways (4, 23-25). The fastest component, which occurs without a measurable delay upon exposure to ACh, represents a specific property of the pathway under study.

The key properties of fast desensitization are defined in Fig. 1. 1A shows a representative response of a native myocyte to a saturating concentration of ACh (10 µM) superfused for 50 s. After rapid activation of inward IK(ACh), the current decayed to a quasi steady-state level of 54% of the peak value. The decay could be approximated by a single exponential with a half-time of 5.28 ± 0.43 s (n = 30). A second slower phase of desensitization within the short period of time contributed to the total decay in current with less than 5% and thus could be ignored when exposure to ACh did not exceed 1 min or so.



View larger version (28K):
[in this window]
[in a new window]
 
Fig. 1.   Properties of fast desensitization of atrial IK(ACh). Panel A, original trace showing desensitizing inward current induced by rapid superfusion with 10 µM ACh-containing solution and complete recovery from desensitization 30 s after washout. Panel B, heterologous nature of fast desensitization. Concentrations of ACh and adenosine were 10 and 100 µM, respectively. The arrow indicates the amplitude of adenosine-induced IK(ACh). Rapid vertical deflections represent changes in membrane current induced by voltage ramps from -120 to + 60 mV, which were routinely superimposed and served to identify IK(ACh) by its strongly inward rectifying I/V relation and to check for stability of the recording conditions. In most figures these have been cut off for graphical reasons. Panel C, representative response of a cell to two consecutive exposures to a high concentration of ACh (100 µM) for ~2 min; a, low speed recording of membrane current; b, superimposed rising phases on an expanded time base. Numbers correspond to the labeling in a. The trace labeled 2 has been scaled up vertically to match the amplitude of 1.

We have shown previously that this second component is likely to reflect desensitization of the M2AChR (4). A characteristic feature of fast desensitization of atrial IK(ACh) is its rapid reversibility. 30 s after starting washout of ACh-containing solution, a second challenge by the agonist resulted in a current of identical amplitude, i.e. rapid desensitization was reversed as soon as IK(ACh) had decayed to its basal level. Longer periods of exposure to ACh and/or substantially higher concentrations could result in a significant reduction of the second response, most likely because of receptor desensitization.

A typical experiment, qualitatively representative of 20 myocytes studied using such a protocol, is illustrated in Fig. 1C. The cell was challenged by a high concentration of ACh (100 µM) for about 2 min. A second exposure after an ACh-free period of 140 s resulted in a current of 68% of the initial peak amplitude (C, a); the fast desensitizing component was almost completely abolished. The half time of activation, which, at saturating agonist concentrations, is closely related to functional density of the receptor (4, 19, 23, 26), was increased from 120 to 210 ms (C, b). A slowing in activation rate, however, per se results in a diminution of the fast desensitizing component (19). Therefore, comparing peak currents of two responses elicited in succession provides little reliable information on fast desensitization because receptor desensitization, i.e. a reduction in density of functional receptors, might contribute to reduction of the amplitude of the second response (10).

Another property defining fast desensitization, in contrast to receptor desensitization, is represented by its heterologous nature. Fig. 1B shows that activation of IK(ACh) by 10 µM Ado, a concentration that is saturating for this agonist, via stimulation of A1 receptors, induced a current of about 35% of the peak current that could be induced by ACh. As shown previously, sensitivity to Ado in this system is limited by low density of functional A1 receptors (19). Superfusion of 10 µM ACh in the presence of Ado resulted in a peak inward current of only 70% of the current induced by 2 µM ACh alone. Thus, although the Ado-induced current did not show desensitization in terms of a visible kinetic component, the system was desensitized by exposure to Ado within few seconds. This subadditive behavior, first described by Kurachi et al. (27), has been found for various combinations of receptor agonists, such as M2AChR/sphingolipid, or M2AChR/beta -adrenergic (21, 28). These properties of fast desensitization are contradictory to the hypothesis that it is mediated by stimulation of a muscarinic M3 receptor, unless one would assume that stimulation of each receptor causing activation of IK(ACh) is paralleled by costimulation of a Gq/11-coupled subtype causing desensitization.

Inhibition of IK(ACh) by alpha 1-Adrenergic Receptors and ETA Receptors-- On principle, information on how activation of PLC interferes with IK(ACh) can be obtained by stimulation of any type of putative PLC-linked receptor expressed in the system under study. In line with a previous publication (29), stimulation of alpha 1-adrenergic receptors resulted in a small activation of IK(ACh) and, concomitantly, an inhibition of IK(ACh) activated by brief pulses of ACh. A representative example is illustrated in Fig. 2. Whereas there was distinct inhibition in all experiments of this type, the activation could be very small or absent. Effects comparable to those observed upon alpha 1-adrenergic stimulation were evoked by endothelin-1 (ET-1) (not shown, compare Fig. 3) in line with a previous publication (30).



View larger version (23K):
[in this window]
[in a new window]
 
Fig. 2.   Simultaneous activation and inhibition of IK(ACh) by Phe. 2 µM ACh and 100 µM Phe were superfused as indicated. The arrowhead denotes a gap of 30 s in duration in the recording. The identities of currents activated by ACh and Phe were verified by their identical current-voltage relations (not shown).



View larger version (19K):
[in this window]
[in a new window]
 
Fig. 3.   Inhibition of IK(ACh) in GTPgamma S-loaded myocytes by Phe and ET-1. Pipette-filling solutions contained 500 µM GTPgamma S. Panel A, representative recording showing stable, irreversible activation of IK(ACh) by repetitive exposure of a myocyte to 2 µM ACh. Panels B and C, representative traces showing inhibition of IK(ACh) by 100 µM Phe and by 10 nM ET-1.

To study the inhibitory effect of the alpha 1-adrenergic agonist or ET-1 in isolation and to obtain information on its kinetic properties, IK(ACh) was routinely activated by loading the cells with the hydrolysis-resistant GTP analogue GTPgamma S. To accelerate activation, the cells were repetitively exposed to ACh until a steady current level was reached. Fig. 3A shows a control trace. Once activated, the current remained fairly constant for several minutes of recording. The sample traces in Fig. 3, B and C, illustrate that 100 µM phenylephrine (Phe) and 10 nM ET-1 both caused an inhibition of IK(ACh). A comparable effect was also found if 100 µM methoxamine was used as alpha -agonist (not shown).The summarized data in Fig. 4A demonstrate that both, alpha 1-adrenergic stimulation as well as stimulation of ETA receptors caused inhibition of IK(ACh) in GTPgamma S-loaded myocytes to about the same degree and with identical time course. The mean half-times of inhibition were 53.4 ± 7.9 s (Phe, n = 10) and 57.3 ± 8.8 s (ET-1, n = 10), respectively. On average, the GTPgamma S-activated current in the absence of Phe or ET-1, respectively, decayed spontaneously by ~20% within 3 min (Fig. 4A). The identical kinetics of inhibition by the two receptor agonists suggest that it is not determined by the receptor species but by downstream reactions of a common signaling pathway. Compared with fast desensitization (compare Fig. 1), inhibition of IK(ACh) by activation of alpha 1-adrenergic or ETA receptors was slower by about 1 order of magnitude. The slow time course of inhibition is unlikely to reflect slower activation of the G protein coupling to these receptors when GTP is exchanged by GTPgamma S. At least for the M2AChR-Gi/o pathway, using activation of IK(ACh) as an assay, activation rates were identical few seconds after breaking the patch under the pipette, i.e. before equilibration of the cytosol with GTPgamma S, and about 30 s later, when the response to ACh was completely irreversible, as shown in Fig. 4B,which is qualitatively representative of 10 experiments using such a protocol.



View larger version (22K):
[in this window]
[in a new window]
 
Fig. 4.   Panel A, time course of IK(ACh) inhibition by Phe and ET-1, summarized from experiments as shown in Fig. 3. As a routine, Phe or ET-1 was applied ~60 s after getting access to the cytoplasm by rupturing the patch under the tip of the patch clamp pipette. This corresponds to time zero in plots of fractional current versus time also for the control group. Data represent mean values ± S.D. (n = 10 for each group). Panel B, activation of IK(ACh), i.e. receptor-controlled activation of Gi/o, is fast in myocytes loaded with GTPgamma S. a, low speed recording of membrane current. The first challenge by 10 µM ACh started 4 s after rupturing the patch under the recording pipette, i.e. when the concentration of GTPgamma S should be low, and activation of Gi/o should predominantly reflect GTP binding. The rate of activation upon a second exposure, 23 s after washout, was identical, as illustrated by the expanded traces (b). The response labeled 2 has been expanded vertically and superimposed on response 1. A third exposure to ACh (3) demonstrates that the current was activated maximally by the second exposure.

The slow decay of GTPgamma S-activated IK(ACh) by about 20% within 3 min in the control group could reflect an inhibitory effect caused by costimulation of putative intrinsic Gq/11-coupled muscarinic receptors. However, exposure of a GTPgamma S-loaded cell to a high concentration of ACh (100 µM), following activation of IK(ACh) either by ACh at a low concentration (2 µM) or by adenosine via A1 receptors, i.e. without prior muscarinic stimulation, did not cause any inhibition, as shown in Fig. 5. After activation by adenosine and subsequent exposure to 100 µM ACh, the decrease in current after 3 min was 16.2 ± 4.8% (n = 6), which was not significantly different from the decrease without exposure to ACh (18.1 ± 4.2%, n = 12). We propose that the slight "spontaneous" decay of IK(ACh) resulted from slow receptor-independent activation by GTPgamma S of the G protein involved in the inhibitory pathway. In contrast to a recent report (10), from the data presented so far there is no evidence that intrinsic M3AChRs are involved in regulating IK(ACh) in adult atrial myocytes.



View larger version (28K):
[in this window]
[in a new window]
 
Fig. 5.   ACh does not cause inhibition of IK(ACh). Panel A, in a GTPgamma S-loaded myocyte IK(ACh) was activated by a brief (4-s) pulse of 2 µM ACh. Activation was maximal because before application of ACh the cell had been dialyzed with GTPgamma S for 15 s, which caused some "spontaneous" inward current. The dashed line indicates the current level immediately after rupturing the membrane patch. 100 µM ACh applied for 2 min did not cause inhibition, but a subsequent exposure to 100 µM Phe resulted in a decrease in current by about 2 nA. Panel B, IK(ACh) in a GTPgamma S-dialyzed myocyte was activated maximally by three exposures to 100 µM Ado. 100 µM ACh failed to cause inhibition. 2 mM BaCl2 was applied briefly in this experiment to measure the background current level.

Whereas the M2AChR represents the classic cardiac ACh receptor, the issue of expression of other subtypes in cardiac myocytes is controversial. Identification of subtypes on pharmacological grounds only is problematic, as selectivity of the ligands presently available is limited (see Fig. 7). Moreover, positive data on global M3AChR expression in the heart, without identification of the cell type, are functionally meaningless. In rat ventricular myocytes no M3AChR transcripts were detected using single cell RT-PCR, which was confirmed by Southern blot analysis and immunocytochemistry, whereas these cells were positive for both M1AChR and M2AChR (31). Corresponding data are not available for atrial myocytes.

In atrial myocytes collected under optical control no M3AChR transcripts could be detected in the RT-PCR products, as shown in Fig. 6A. This gel, which is representative of five experiments, is negative for M3AChR transcripts in identified atrial myocytes, whereas transcripts for GAPDH and M2AChR could be detected. On the other hand, using the same primers, M3AChR transcripts could be detected in samples obtained from suspended cultures (Fig. 6B), which might reflect expression of this subtype in vascular smooth muscle and/or endothelial cells, which contaminate the cultures, though at a low level. Although negative RT-PCR data alone cannot be taken as a proof that the corresponding protein is not expressed, the lack of a signal supports our conclusion drawn from the functional data that in adult rat atrial myocytes ACh does not stimulate a Gq/11-coupled muscarinic receptor subtype.



View larger version (62K):
[in this window]
[in a new window]
 
Fig. 6.   Panel A, gel electrophoresis of RT-PCR products amplified from identified atrial myocytes. As described under "Experimental Procedures," 10 myocytes had been picked under optical control for the RT reaction. The solution containing the RT products was split and used in two different PCRs with either primers for the M2AChR and GAPDH (second and third lanes from the left) or M3AChR and GAPDH (fourth and fifth lanes). Panel B, the message for the M3AChR is apparent in RT-PCR products from samples of suspended atrial cultures (rightmost lane) but not in atrial myocytes (second from left), which are positive for GAPDH (third lane).

The hypothesis that fast desensitization in atrial cells is mediated by M3AChR (10) was primarily based on pharmacological evidence. 4-DAMP, a compound described as a selective M3AChR antagonist, in that study resulted in a reduction of desensitization or a desensitizing component of ACh-induced IK(ACh) in atrial cells. As shown in Fig. 7, however, selectivity of 4-DAMP for muscarinic receptor subtypes is poor. This compound, at 10 nM, caused a reversible reduction of the current induced by 2 µM ACh by about 40%. As with any other muscarinic antagonist, such as atropine, inhibition of the current by 4-DAMP was paralleled by slowing of activation and blunting of the rapidly desensitizing component. Because the current in GTPgamma S-loaded myocytes was not sensitive to 4-DAMP (not shown) the compound most likely also acts as an M2AChR antagonist. This is in line with the reported inhibition constants ranging from 4 × 10-9 M to 1.6 × 10-8 M for the M2AChR and from 1.2 × 10-9 M to 5 × 10-10 for the M3AChR (32). Thus, despite its frequent use as pharmacological tool, this compound is not sufficiently selective to be suitable for discriminating between M3AChR and M2AChR.



View larger version (18K):
[in this window]
[in a new window]
 
Fig. 7.   4-DAMP reversibly inhibits IK(ACh) and blunts the fast desensitizing component. Pipette-filling solution contained 50 µM GTP. 10 µM ACh and 10 nM 4-DAMP were applied as indicated.

Inhibition of IK(ACh) Is Mediated by the PLC-linked Signaling Pathway-- alpha 1-Adrenergic receptors and ETA receptors are supposed to couple preferentially but not exclusively to G proteins of the Gq/11 family. The subsequent step in the common pathway controlled by this class of G proteins is activation of PLCbeta , yielding the second messengers inositol (3,4,5)trisphosphate (InsP3) and diacylglycerol from hydrolysis of PtIns(4,5)P2. To verify the contribution of this class of G proteins to inhibition of IK(ACh), myocytes were pretreated with P. multocida toxin, a protein toxin that has been described to uncouple Gq proteins from their receptors, presumably by first causing activation followed by a modification that prevents reactivation after deactivation (33, 34). In cells pretreated with the toxin (1 µg/ml for ~ 20 h), activation of IK(ACh) by M2AChR and/or intracellular GTPgamma S was not affected (Fig. 8). However, inhibition of IK(ACh) by 100 µM Phe was completely abolished. This was also confirmed in four experiments using 10 nM ET-1 (not shown). Contribution of Gq/11 to mediating the inhibition is consistent with the notion that activation of PLC represents the subsequent signaling step, although contributions by alternative mechanisms cannot be ruled out a priori, such as direct inhibitory actions of Gbeta gamma dimers containing the beta 5 subunit (35). A frequently used PLC inhibitor is the aminosteroid U 73122. Because many side effects not related to inhibition of PLC have been described for this compound, its use as pharmacological tool is limited and requires careful control experiments. This compound has been used previously to support the hypothesis that activation of PLC by M3AChR and subsequent depletion of PtIns(4,5)P2 represent the mechanism of fast desensitization. As shown in Fig. 9, however, U 73122 at 1 µM caused a reduction in GTPgamma S-activated IK(ACh) by about 50%. Although this was not investigated further in detail, this compound is likely to act as a blocker of Kir3.0 channels and thus is not suited as a tool to study PLC-related effects in this system.



View larger version (20K):
[in this window]
[in a new window]
 
Fig. 8.   alpha -Receptor-induced inhibition of IK(ACh) is abolished by treatment with P. multocida toxin. Panel A, representative current recording from a myocyte treated with the 1 µg/ml toxin (>= 20 h). 10 µM ACh and 100 µM Phe were applied as indicated. Panel B, summarized data. Untreated cells were from the same batches as P. multocida toxin-treated cells. The difference between the control group and the P. multocida toxin-treated group was not significant.



View larger version (24K):
[in this window]
[in a new window]
 
Fig. 9.   Inhibition of GTPgamma S-activated IK(ACh) by U 73122. The current was activated by brief exposure to ACh as in Fig. 2 (not shown). U 73122 was applied as indicated.

Receptor-induced Inhibition of IK(ACh) Is Reduced by PtIns(4,5)P2-- We next tried to obtain further information on the signaling mechanism subsequent to underlying slow inhibition of IK(ACh) via Gq/11-coupled receptors. Whereas InsP3 is the ubiquitous Ca2+-mobilizing second messenger, diacylglycerol causes activation of protein kinase C. 100 µM 12-O-tetradecanoylphorbol-13-acetate, a potent activator of PKC, in 10 cells studied failed to mimic the effects of alpha -adrenergic agonists or ET-1, respectively (not shown), suggesting that protein kinase C is not causally involved. As in the present study a moderate pipette Ca2+-buffering capacity (2 mM EGTA) was used, Ca2+ released from InsP3-sensitive stores as mediator cannot be excluded. Supplementing the pipette solution with a 10 mM concentration of the fast Ca2+ chelator BAPTA did not affect inhibition of IK(ACh) by Phe (10 cells, not shown), suggesting that Ca2+-dependent processes are not involved.

In a number of recent publications evidence has been provided that PtIns(4,5)P2 represents a cofactor for activation of Kir3.0 channels by Gbeta gamma (11, 36) and is also required for activity of other inward rectifying K+ channels (13, 16, 17, 37, 38). We therefore studied whether loading of atrial myocytes with PtIns(4,5)P2 via the pipette filling solution affects properties of macroscopic IK(ACh) and/or alpha 1-adrenergic inhibition. Fig. 10A demonstrates that inclusion of PtIns(4,5)P2 (nominally 500 µM) in the pipette without GTPgamma S had no effect on amplitude and desensitization properties of IK(ACh). This was found in six out of six myocytes loaded with PtIns(4,5)P2. On the other hand, supplementation of the pipette solution with PtIns(4,5)P2 caused a significant reduction of the Phe-induced inhibition of GTPgamma S-activated IK(ACh). Representative traces from this series of experiments are shown in Fig. 10B. As shown in Figs. 2 and 4, 100 µM Phe caused an inhibition of steady-state IK(ACh) by about 70% (C). These data suggest first that under normal conditions the concentration of PtIns(4,5)P2 in the membrane is not a limiting factor for activation of IK(ACh). Second, inhibition of IK(ACh) by heptahelical receptors activating PLC is caused by depletion of PtIns(4,5)P2. Moreover, depletion of PtIns(4,5)P2 is not causally related to fast desensitization.



View larger version (18K):
[in this window]
[in a new window]
 
Fig. 10.   Loading of myocytes with PtIns(4,5)P2. Panel A, receptor-activated IK(ACh) in the absence of intracellular GTPgamma S is not affected by supplementing the pipette solution with PtIns(4,5)P2. The first response to ACh was induced within 6 s after rupturing the patch under the recording pipette. Panel B, inhibition of GTPgamma S-activated IK(ACh) is reduced by adding PtIns(4,5)P2 to the pipette solution (representative recording). Panel C, control measurement from a cell of the same batch as B without PtIns(4,5)P2. Panel D, summarized data (n = 6 for either group).



    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The present study has provided evidence that activation of alpha -adrenergic and ETA receptors causes inhibition of atrial IK(ACh) by depletion of PtIns(4,5)P2. The rate of inhibition with a half-time of around 50 s was identical for the two receptors, suggesting a common signaling mechanism. Interestingly, the rate of inhibition was similar to the rate of inhibition of heterologously expressed K(ATP) channels by stimulation of coexpressed M1AChR receptors, described recently as an example of a receptor-controlled signal that is mediated via depletion of PtIns(4,5)P2 (17).

The GIRK (Kir3.0) channel complex represents the paradigmatic target of G protein beta gamma subunits. It is generally assumed that physiological activation of Kir3.0 channels is specific to beta gamma subunits of pertussis toxin-sensitive G proteins (Gi/o), although examples of activation under certain conditions of atrial IK(ACh) via the Gs pathway have been presented recently (28, 39).

Apart from Gbeta gamma regulation, channel activity has been shown to be modulated by PtIns(4,5)P2 and intracellular [Na+]. Sensitivity to PtIns(4,5)P2 has also been demonstrated for other members of the Kir channel family (12, 15, 16, 37). It remained unclear, however, whether PtIns(4,5)P2 is a necessary cofactor for Kir channels or if PtIns(4,5)P2 acts as a signaling molecule in terms of a second messenger. More recently, Xie et al. (17) demonstrated that PLC-coupled receptors can regulate K(ATP) channels composed of Kir6.2 and SUR2A subunits via depletion of PtIns(4,5)P2 in an heterologous expression system, providing direct evidence that phosphoinositides act as messengers in a receptor-controlled signaling pathway. The physiological relevance of modulation of Kir channels by PtIns(4,5)P2 was also demonstrated in an elegant study on expressed K(ATP) channels (37). These authors found a decrease in ATP sensitivity of K(ATP) in cells coexpressing a phosphoinositide-4-phosphate 5-kinase, which contributes to up-regulating the levels of PtIns(4,5)P2 and other phosphoinositides.

The notion of a second messenger role of PtIns(4,5)P2 was supported by Kobrinsky et al. (10), who reported that activation of PLC-coupled receptors caused fast desensitization of native IK(ACh) in rat neonatal myocytes and Kir3.1/Kir3.4 currents expressed in a cell line. According to that study, fast desensitization of M2AChR-activated IK(ACh) in atrial myocytes results from PLC activation via costimulation of a PLC-linked muscarinic receptor subtype (M3AChR). The present findings confirm that activation of PLC-coupled receptors causes inhibition of atrial IK(ACh) in a PtIns(4,5)P2-sensitive manner. However, they disprove the hypotheses that intrinsic M3AChRs are involved in regulation of atrial IK(ACh) and that PtIns(4,5)P2-depletion causes fast desensitization.

First, fast desensitization of atrial IK(ACh) at room temperature has a half-time of in the order of 5 s, whereas inhibition of IK(ACh) by stimulation of PLC-linked receptors was slower by a factor of 10. The slow rate of inhibition is an intrinsic property of the signaling pathway and does not result from the experimental condition (loading with GTPgamma S) because the rate of signaling via Gi/o was not affected by this condition.

Second, ACh did not induce a measurable inhibition of IK(ACh).

Third, we have shown previously that atrial IK(ACh), activated by A1 receptors, displays fast desensitization, which was increased in myocytes overexpressing the A1 receptor (19).

With a background of these results any contribution of intrinsic PLC-coupled muscarinic receptors to fast desensitization can be safely excluded. Moreover, the lack of any inhibition of atrial IK(ACh) by ACh, in contrast to alpha -agonists or ET-1, and the negative RT-PCR for M3AChR transcripts argue against expression of this receptor in rat atrial myocytes.

GIRK currents generate inhibitory postsynaptic potentials, which are shaped by different phases of desensitization in terms of an adaptation to synaptic inputs. The term desensitization is a phenomenological one. It comprises ultrarapid conformational changes on the microsecond time scale of ionotropic receptor/channel proteins, such as the nicotinic ACh receptor, to phosphorylation-initiated reductions in sensitivity of a cell to a stimulus on the time scale of hours as, e.g. in case of the paradigmatic beta -adrenergic receptors, but also in the pathway that is subject to the present investigation.

Both the instantaneous onset of acute desensitization and its fast recovery argue against phosphorylation/dephosphorylation of the channel complex, as suggested previously (7, 40). The most convincing concept to date suggests that fast desensitization is caused by the kinetics of the nucleotide exchange and hydrolysis cycle of the G protein (9). The model proposed by these authors takes into account that fast desensitization is closely linked to activation of the current. Although attractive, this model does not describe all of the properties of IK(ACh) in a native myocyte. According to that model, GTPgamma S-induced IK(ACh) should be larger, and in the presence of the GTP analog, fast desensitization should be abolished. Our data (e.g. Figs. 5 and 10) suggest that steady-state currents in GTPgamma S-loaded myocytes are smaller than peak currents activated by ACh. Moreover, desensitization is not abolished by GTPgamma S. Therefore further experimental work is required to clarify the mechanism of fast desensitization.

The present study confirms a second messenger role of PtIns(4,5)P2. Dual regulation of Kir3.0 currents by stimulatory Gi/o-coupled receptors via Gbeta gamma and by inhibitory Gq/11-coupled receptors via PtIns(4,5)P2 depletion represents a novel concept of synaptic integration at the level of an ion channel.


    ACKNOWLEDGEMENTS

We thank Anke Galhoff, Bing Liu, and Gabriele Reimus for expert technical assistance.


    Addendum

While the present publication was under review, a paper was published which provided strong evidence for alpha -adrenergic inhibition of IK(ACh) via depletion of PtIns(4,5)P2 in mouse atrial myocytes (41).


    FOOTNOTES

* This work was supported by Grant Po 212/9-3 from the Deutsche Forschungsgemeinschaft.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed. Tel.: 49-234-322-9200; Fax: 49-234-321-4449; E-mail: lutz.pott@ruhr-uni-bochum.de.

Published, JBC Papers in Press, December 4, 2000, DOI 10.1074/jbc.M009179200


    ABBREVIATIONS

The abbreviations used are: GIRK, G protein-gated inward rectifier K+ channel; ACh, acetylcholine; IK(ACh), inwardly rectifier K+ current upon stimulation with acetylcholine; M2AChR and M3AChR, muscarinic M2 and M3 receptor, respectively; PLC, phospholipase C; PtdIns(4, 5)P2, phosphatidylinositol 4,5-bisphosphate; GTPgamma S, guanosine 5'-3-O-(thio)triphosphate); 4-DAMP, 4-diphenylacetoxy-N-methylpiperidine; RT, reverse transcriptase; PCR, polymerase chain reaction; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; ET, endothelin; Phe, phenylephrine; InsP3, inositol (3,4,5)bisphosphate; BAPTA, 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES


1. Jan, L. Y., and Jan, Y. N. (1997) J. Physiol. (Lond.) 505, 267-282[Free Full Text]
2. Yamada, M., Inanobe, A., and Kurachi, Y. (1998) Pharmacol. Rev. 50, 723-757[Abstract/Free Full Text]
3. Karschin, A. (1999) News Physiol. Sci. 14, 215-220[Abstract/Free Full Text]
4. Bünemann, M., Brandts, B., and Pott, L. (1996) J. Physiol. (Lond.) 492, 351-362
5. Bünemann, M., and Hosey, M. M. (1999) J. Physiol. (Lond.) 517, 5-23[Free Full Text]
6. Böhm, S. K., Grady, E. F., and Bunnett, N. W. (1997) Biochem. J. 322, 1-18[Medline] [Order article via Infotrieve]
7. Shui, Z., Boyett, M. R., and Zang, W. J. (1997) J. Physiol. (Lond.) 505, 77-93[Abstract]
8. Hong, S. G., Pleumsamran, A., and Kim, D. (1996) Am. J. Physiol. 270, H526-H537[Abstract/Free Full Text]
9. Chuang, H., Yu, M., Jan, Y. N., and Jan, L. Y. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 11727-11732[Abstract/Free Full Text]
10. Kobrinsky, E., Mirshahi, T., Zhang, H., and Logothetis, D. E. (2000) Nature Cell Biol. 2, 507-514[CrossRef][Medline] [Order article via Infotrieve]
11. Sui, J. L., Petit-Jacques, J., and Logothetis, D. E. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 1307-1312[Abstract/Free Full Text]
12. Rohács, T., Chen, J., Prestwich, G. D., and Logothetis, D. E. (1999) J. Biol. Chem. 274, 36065-36072[Abstract/Free Full Text]
13. Zhang, H., He, C., Yan, X., Mirshahi, T., and Logothetis, D. E. (1999) Nature Cell Biol. 1, 183-188[CrossRef][Medline] [Order article via Infotrieve]
14. Shyng, S. L., and Nichols, C. G. (1998) Science 282, 1138-1141[Abstract/Free Full Text]
15. Baukrowitz, T., Schulte, U., Oliver, D., Herlitze, S., Krauter, T., Tucker, S. J., Ruppersberg, J. P., and Fakler, B. (1998) Science 282, 1141-1144[Abstract/Free Full Text]
16. Leung, Y. M., Zeng, W. Z., Liou, H. H., Solaro, C. R., and Huang, C. L. (2000) J. Biol. Chem. 275, 10182-10189[Abstract/Free Full Text]
17. Xie, L. H., Horie, M., and Takano, M. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 15292-15297[Abstract/Free Full Text]
18. Kurachi, Y., Nakajima, T., and Sugimoto, T. (1986) Pfluegers Arch. Eur. J. Physiol. 407, 264-274[Medline] [Order article via Infotrieve]
19. Wellner-Kienitz, M.-C., Bender, K., Meyer, T., Bünemann, M., and Pott, L. (2000) Circ. Res. 86, 643-648[Abstract/Free Full Text]
20. Bünemann, M., Brandts, B., Meyer zu Heringdorf, D., Van Koppen, C. J., Jakobs, K. H., and Pott, L. (1995) J. Physiol. (Lond.) 489, 701-707[Abstract]
21. Bünemann, M., Liliom, K., Brandts, B., Pott, L., Tseng, J.-L., Desiderio, G. M., Sun, G., Miller, D., and Tigyi, G. (1996) EMBO J. 15, 5527-5534[Abstract]
22. Himmel, H. M., Meyer Zu, H. D., Graf, E., Dobrev, D., Kortner, A., Schuler, S., Jakobs, K. H., and Ravens, U. (2000) Mol. Pharmacol. 58, 449-454[Abstract/Free Full Text]
23. Bünemann, M., Brandts, B., and Pott, L. (1997) J. Physiol. (Lond.) 501, 549-554[Abstract]
24. Bünemann, M., Lee, K. B., Pals-Rylaarsdam, R., Roseberry, A. G., and Hosey, M. M. (1999) Annu. Rev. Physiol. 61, 169-192[CrossRef][Medline] [Order article via Infotrieve]
25. Pitcher, J. A., Freedman, N. J., and Lefkowitz, R. J. (1998) Annu. Rev. Biochem. 67, 653-692[CrossRef][Medline] [Order article via Infotrieve]
26. Bünemann, M., and Pott, L. (1995) J. Physiol. (Lond.) 482, 81-92[Abstract]
27. Kurachi, Y., Nakajima, T., and Sugimoto, T. (1987) Pfluegers Arch. Eur. J. Physiol. 410, 227-233[Medline] [Order article via Infotrieve]
28. Wellner-Kienitz, M.-C., Bender, K., Brandts, B., Meyer, T., and Pott, L. (1999) FEBS Lett. 451, 279-283[CrossRef][Medline] [Order article via Infotrieve]
29. Braun, A. P., Fedida, D., and Giles, W. R. (1992) Pfluegers Arch. Eur. J. Physiol. 421, 431-439[Medline] [Order article via Infotrieve]
30. Yamaguchi, H., Sakamoto, N., Watanabe, Y., Saito, T., Masuda, Y., and Nakaya, H. (1997) Am. J. Physiol. 273, H1745-H1753[Abstract/Free Full Text]
31. Sharma, V. K., Colecraft, H. M., Wang, D. X., Levey, A. I., Grigorenko, E. V., Yeh, H. H., and Sheu, S. S. (1996) Circ. Res. 79, 86-89[Abstract/Free Full Text]
32. Brodde, O.-E., and Michel, M. C. (1999) Pharmacol. Rev. 51, 651-689[Abstract/Free Full Text]
33. Wilson, B. A., Zhu, X., Ho, M., and Lu, L. (1997) J. Biol. Chem. 272, 1268-1275[Abstract/Free Full Text]
34. Bünemann, M., Meyer, T., Pott, L., and Hosey, M. M. (2000) J. Biol. Chem. 275, 12537-12545[Abstract/Free Full Text]
35. Lei, Q., Jones, M. B., Talley, E. M., Schrier, A. D., McIntyre, W. E., Garrison, J. C., and Bayliss, D. A. (2000) Proc. Natl. Acad. Sci. U. S. A. 15, 9771-9776[CrossRef]
36. Petit-Jacques, J., Sui, J. L., and Logothetis, D. E. (1999) J. Gen. Physiol. 114, 673-684[Abstract/Free Full Text]
37. Shyng, S.-L., Barbieri, A., Gumusboga, A., Cukras, C., Pike, L., Davis, J. N., Stahl, P. D., and Nichols, C. G. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 937-941[Abstract/Free Full Text]
38. Hilgemann, D. W., and Ball, R. (1996) Science 273, 956-959[Abstract]
39. Sorota, S., Rybina, R., Yamamoto, A., and Du, X.-Y. (1999) J. Physiol. (Lond.) 514, 413-423[Abstract/Free Full Text]
40. Kim, D. (1993) Circ. Res. 73, 89-97[Abstract]
41. Cho, H., Nam, G.-B., Lee, S. H., Earn, Y. E., and Ho, W.-K. (2001) J. Biol. Chem. 276, 159-164[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.